LATE-BREAKING ABSTRACT: Safety and efficacy of inhaled mannitol over 12 months in high-risk patients with non-CF bronchiectasis

A. De Soyza, A. Barker, D. Chambers, C. Brent, H. Fox, F. Howard, T. Welte, D. Bilton (Newcastle-upon-Tyne, London, United Kingdom; Portland, United States Of America; Herston, Frenchs Forest, Australia; Hannover, Germany)

Source: International Congress 2014 – Latest insights in airway diseases
Session: Latest insights in airway diseases
Session type: Thematic Poster Session
Number: 2814
Disease area: Airway diseases, Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. De Soyza, A. Barker, D. Chambers, C. Brent, H. Fox, F. Howard, T. Welte, D. Bilton (Newcastle-upon-Tyne, London, United Kingdom; Portland, United States Of America; Herston, Frenchs Forest, Australia; Hannover, Germany). LATE-BREAKING ABSTRACT: Safety and efficacy of inhaled mannitol over 12 months in high-risk patients with non-CF bronchiectasis. Eur Respir J 2014; 44: Suppl. 58, 2814

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effects of inhaled salmeterol/fluticasone on lung function in patients with bronchiectasis
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014


LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

LATE-BREAKING ABSTRACT: Outcome of withdrawal of one inhaler in COPD patients received combined ICS/LABA and LAMA
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014


Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014

LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014

Safety of tiotropium in renally impaired patients
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013


Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014

1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



LATE-BREAKING ABSTRACT: A phase 2a study of benralizumab in adults with COPD
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014


Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: Lung function and safety
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013


Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014